Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Passage Bio, Inc. - Common Stock (NQ:PASG)

7.060 +0.060 (+0.86%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Passage Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q2 2024
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Recap: Passage Bio Q3 Earnings
 
Via Benzinga
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
From Passage Bio
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning! 
Via InvestorPlace
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot. 
Via InvestorPlace
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
Although nano-cap stocks are super-risky just like stealing bases in baseball, there may be a time and place for extreme speculation. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results. 
Via Benzinga
Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities
Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
From Passage Bio
Via GlobeNewswire
Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.